Nobody puts cancer in a corner!
Enticing monetary donations out of homeowners in exchange for address labels remains a staple in philanthropic fundraising. But the Stand Up To Cancer (SU2C) organization has taken a more modern approach to recruiting support through online social networking.
Enticing monetary donations out of homeowners in exchange for address labels remains a staple in philanthropic fundraising. But the Stand Up To Cancer (SU2C) organization has taken a more modern approach to recruiting support through online social networking. Their “Virtual Stand Up” invites users to join the group’s FaceBook page, create a YouTube video, or send a real-time, short message called a “tweet.” A $1 donation nets a personalized “star” in SU2C’s virtual constellation.
Articles in this issue
Nanoparticles extend survival in pancreatic ca patients
Nobody puts cancer in a corner!
ACS spends big money to highlight healthcare system deficiencies
Visits to oncologists up, but profit per patient is on the decline
Report finds high rate of adoption of IMRT
Some HER2+ tumors prove resistant to trastuzumab
NIH bankrolls molecular probes for targeted therapy
Oropharyngeal ca: IMRT spares salivary glands
Fear of audit, lazy billing erodes profits
Apoptosis inducer hits melanoma with double whammy
Triathlon for an MPD cure
Oncology electronic health records: More than just an e-secretary
Barrie Cassileth, an integrative medicine pioneer
Move to make CME an out-of-pocket cost gains ground
Is concurrent chemotherapy/IMRT too toxic and dangerous for use in H&N cancer?
Recent Videos
The Evolution of EGFR-Mutated Advanced NSCLC Treatment: Present Considerations and Future Treatment Options
FDA Approvals for Multiple Myeloma
Treatment Approaches in Multiple Myeloma
MonumenTAL-1: Outcomes From the Extended Median Follow-Up Data (Part 2)
MonumenTAL-1: Outcomes From the Extended Median Follow-Up Data
Talquetamab in R/R MM: Managing GPRC5D-direced AEs, Prophylaxis, and New Safety Signals
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
JNJ-5322 Shows Efficacy in Later-Line Multiple Myeloma
Safety Updates and Concluding Thoughts From Extended Follow-Up of MonumenTAL-1
MRD Recurrence Shown to Precede Biochemical Relapse in Multiple Myeloma
JNJ-5322 Improves Efficacy, Oral Toxicity in Multiple Myeloma
Related Content
